1 mins to read

Douglas signs new cancer drug R&D deal with Manchester University

International roll-out could cost more than tens of millions of dollars.

Paul McBeth
Wed, 01 Feb 2017

Douglas Pharmaceuticals has signed a research and licensing deal with the University of Manchester's innovation unit, UMI3, to repurpose an HIV drug to prevent early-stage cervical cancer.

Auckland-based Douglas Pharmaceuticals will sponsor research at Manchester University to build on work that's found a drug commonly used to treat HIV is active against human papilloma virus (HPV), which causes almost all cases of cervical cancer.

Douglas Pharmaceuticals will then manufacture the therapy and push development, clinical trials and global commercialisation, focusing at first on a phase two clinical trial in the UK.

Chief executive Jeff Douglas says the company has been working with Manchester University for almost two years, and if clinical trials in American and European centres are successful, then they will partner with a multinational company for an international roll-out that could cost "more than tens of millions of dollars."

Mr Douglas says the Gardasil HPV vaccine had been successful in reducing cervical cancer where it had been rolled out, primarily in the US and Europe, although it is still a relatively new treatment in developed economies.

"There will be other patients requiring treatment that haven't been protected in poorer countries," he says.

Douglas Pharmaceuticals is on track to reach annual sales of $200 million in the financial year and has previously set a target of $244 million in revenue by 2020.

Mr Douglas says repurposing existing drugs is "an important addition to our business" and while it's "far more expensive than some other work" the returns are better if it's successful, and it can provide new patent protection.

The company has just set up a new development business in the US, with a team on-board in Pennsylvania, which Mr Douglas says he expects to be operational in three months.


Paul McBeth
Wed, 01 Feb 2017
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Douglas signs new cancer drug R&D deal with Manchester University